SCCA Clinical Studies: Lung Cancer
SCCA was formed, in part, to bring promising new treatments to patients faster. For lung cancer patients this means more treatment options are available at SCCA than might be found elsewhere, including participation in one of many ongoing clinical trials conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.
To find a clinical trial:
- View the Lung Cancer Trial Finder (pictured right), where trials are organized by disease status (e.g., Newly Diagnosed, Advanced Metastatic, etc).
- Click here to view a listing of all open lung cancer trials.
- To see a list of all of SCCA's most recently opened clinical trials, follow our Twitter feed @SCCA_Trials. Likewise, the SCCABlog also regularly lists recently opened trials as well.
Our current high priority trials include:
- CO-1686 for Non-Small Cell Lung Cancer (UW13041)
A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)
- Alisertib (MLN8237) in Combination With Paclitaxel for Small Cell Lung Cancer (UW14002)
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)